ACUTE MYELOGENOUS LEUKAEMIA: MAINTENANCE CHEMOTHERAPY AFTER EARLY CONSOLIDATION TREATMENT DOES NOT PROLONG SURVIVAL
- 18 February 1984
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 323 (8373), 379-382
- https://doi.org/10.1016/s0140-6736(84)90424-0
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Early antiviral antibody response after immunization with viral oncolysate: a powerful prognostic marker for acute myelogenous leukemia remission patientsBlood, 1983
- Intensification therapy for acute nonlymphoblastic leukemia in adultsCancer, 1983
- Marrow Transplant for Acute Nonlymphoblastic Leukemia in First Remission: A Follow-upNew England Journal of Medicine, 1983
- Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB studyBlood, 1982
- Short-term treatment for acute myelogenous leukaemia.BMJ, 1982
- HIGH REMISSION-INDUCTION RATE IN ACUTE MYELOID LEUKÆMIAThe Lancet, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958